August 8, 2025
Omada Health beats on revenue in first earnings report since IPO
The company offers virtual care programs to support patients with chronic conditions.

The Omada Health logo is displayed on a smartphone screen.

Sopa Images | Lightrocket | Getty Images

Omada Health reported quarterly results for the first time since its IPO in June.

Here’s how the company did based on average analysts’ estimates compiled by LSEG:

  • Loss: Loss per share of 24 cents.
  • Revenue: $61 million vs. $55.2 million expected

The virtual care company’s revenue increased 49% in its second quarter from $41.21 million a year earlier. The company reported a net loss of $5.31 million, or a 24-cent loss per share, compared to a net loss of $10.69 million, or $1.40 loss per share, during the same period last year.

“We believe our Q2 performance reflects Omada’s ability to capture tailwinds in cardiometabolic care, to effectively commercialize our GLP-1 Care Track, and to leverage advances in artificial intelligence for the benefit of our members,” Omada CEO Sean Duffy said in a release.

Read more CNBC tech news

For its full year, Omada expects to report revenue between $235 million to $241 million, while analysts were expecting $222 million. The company said it expects to report an adjusted EBITDA loss of $9 million to $5 million for the full year, while analysts polled by FactSet expected a wider loss of $20.2 million.

Omada, founded in 2012, offers virtual care programs to support patients with chronic conditions like prediabetes, diabetes and hypertension. The company describes its approach as a “between-visit care model” that is complementary to the broader health-care ecosystem.

The stock opened at $23 in its debut on the Nasdaq in June. At market close on Thursday, shares closed at $19.46.

Omada said it finished its second quarter with 752,000 total members, up 52% year over year.

The company will discuss the results during its quarterly call with investors at 4:30 p.m. ET.

WATCH: Omada Health CEO Sean Duffy on IPO debut: Today is the right moment for us